Table 1

Baseline demographic and clinical characteristics (24-week PPS)

HD203 (n=115)ETN (n=118)
Mean (SD) age, years51.0 (12.0)51.3 (12.4)
Female gender, n (%)101 (87.8)101 (85.6)
Mean (SD) weight, kg56.5 (9.7)57.2 (9.3)
Mean (SD) BMI, kg/m222.5 (3.4)22.8 (3.5)
ACR functional status, n (%)
 Class I14 (12.2)24 (20.3)
 Class II85 (73.9)71 (60.2)
 Class III16 (13.9)23 (19.5)
RF positive, n (%)94 (81.7)108 (91.5)
Anti-CCP antibody-positive, n (%)100 (87.0)103 (87.3)
RF or anti-CCP antibody-positive, n (%)108 (93.9)115 (97.5)
Mean (SD) C reactive protein, mg/dL2.1 (2.4)1.6 (1.7)
Mean (SD) ESR, mm/h53.2 (25.7)54.0 (29.0)
Mean (SD) tender joint count17.4 (11.2)17.5 (10.7)
Mean (SD) swollen joint count12.5 (7.3)12.2 (6.4)
Disease duration, years
 Mean (SD)7.19 (7.39)8.05 (7.43)
 Median (min, max)4.39 (0.46, 40.88)6.00 (0.44, 34.77)
Steroid use (≤10 mg/day prednisone or equivalent), n (%)100 (86.96)108 (91.53)
Mean (SD) HAQ-DI1.1 (0.7)1.1 (0.7)
  • ACR, American College of Rheumatology; anti-CCP, anti-cyclic citrullinated protein; BMI, body mass index; ESR, erythrocyte sedimentation rate; ETN, etanercept; HAQ-DI, Health Assessment Questionnaire Disability Index; PPS, per-protocol set; RF, rheumatoid factor.